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Abstract 
Background: Resistance to all available anti-malarial drugs has emerged and spread including artemisinin deriva-
tives and their partner drugs. Several genes involved in artemisinin and partner drugs resistance, such as pfcrt, pfmdr1, 
pfK13 or pfpm2, have been identified. However, these genes do not properly explain anti-malarial drug resistance, and 
more particularly clinical failures observed in Africa. Mutations in genes encoding for Plasmodium falciparum proteins, 
such as P. falciparum Acetyl-CoA transporter (PfACT), P. falciparum UDP-galactose transporter (PfUGT) and P. falciparum 
cyclic amine resistance locus (PfCARL) have recently been associated to resistance to imidazolopiperazines and other 
unrelated drugs.
Methods: Mutations on pfugt, pfact and pfcarl were characterized on 86 isolates collected in Dakar, Senegal and 173 
samples collected from patients hospitalized in France after a travel in African countries from 2015 and 2016 to assess 
their potential association with ex vivo susceptibility to chloroquine, quinine, lumefantrine, monodesethylamodi-
aquine, mefloquine, dihydroartemisinin, artesunate, doxycycline, pyronaridine and piperaquine.
Results: No mutations were found on the genes pfugt and pfact. None of the pfcarl described mutations were 
identified in these samples from Africa. The K784N mutation was found in one sample and the K734M mutation was 
identified on 7.9% of all samples for pfcarl. The only significant differences in ex vivo susceptibility according to the 
K734M mutation were observed for pyronaridine for African isolates from imported malaria and for doxycycline for 
Senegalese parasites.
Conclusion: No evidence was found of involvement of these genes in reduced susceptibility to standard anti-malar-
ial drugs in African P. falciparum isolates.
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Background
According to the World Health Organization (WHO) 
recommendations, endemic countries have adopted the 
use of artemisinin-based combination therapy (ACT) 
to treat uncomplicated malaria cases [1]. Despite con-
siderable progress, 219 million new malaria cases were 
reported with 435,000 deaths in 2017 [2]. Currently, arte-
misinin-based combinations are the most potent avail-
able anti-malarial drugs that are used for the reduction 
of the malaria global burden. Combination of a long act-
ing drug with the short acting artemisinin is used to pro-
vide a protection against emergence of resistant parasites 
[3]. Mefloquine, lumefantrine, amodiaquine, and more 
recently piperaquine and pyronaridine are the available 
artemisinin-based partner drugs in ACT. Resistance to 
artemisinin described as a delayed parasite clearance 
after treatment has emerged in Southeast Asia [4, 5]. It 
was also reported that low treatment success rate of ACT 
was associated with resistance to the partner drugs. This 
resistance has been described in Southeast Asia and may 
occur in Africa soon [6, 7].
In 2013, a molecular marker strongly associated with 
artemisinin resistance was identified as mutations in 
the Kelch 13 propeller domain (pfk13) in the Southeast 
Asia, but none of these mutations are yet documented 
in Africa [8, 9]. Pfk13 and/or the Ring-stage Survival 
Assay (RSA) are now used as tools to track artemisinin 
and artemisinin derivatives resistance in endemic areas 
in addition with epidemiological survey. However, 
recent studies proved that pfk13 is not the only marker 
to be associated with artemisinin resistance [10]. Clini-
cal failures with ACT have also been observed in African 
patients with P. falciparum parasites without pfk13 poly-
morphism [11–15]. Polymorphisms in other genes, like P. 
falciparum actin-binding protein coronin, P. falciparum 
ubiquitin carboxyl-terminal hydrolase 1 (pfubp1) or P. 
falciparum clathrin vesicle-associated adaptor 2 µ subu-
nit (pfap2mu), have been also found to be associated with 
artemisinin resistance in African isolates [16, 17].
Additionally, resistance has also emerged to dihydroar-
temisinin–piperaquine, the most recently marketed 
ACT, in Cambodia and Vietnam [18–21]. In  vitro and 
in  vivo resistance to piperaquine has been associated 
with amplification of copy number of the plasmepsin II 
gene (pfpm2) in Cambodian isolates [22, 23]. However, 
amplification of this gene seems to be not associated with 
piperaquine in  vitro and in  vivo resistance particularly 
in Africa [24–29]. In conclusion, predictive molecular 
markers to track resistance to ACT in Africa are not yet 
identified.
Drug efficacy is modulated by parasite membrane 
proteins that are involved in drug transport. Two para-
sites membrane proteins, the Plasmodium falciparum 
chloroquine resistance transporter (PfCRT) and the P. 
falciparum multidrug resistance protein 1 (PfMDR1), 
both localized on the membrane of the digestive food 
vacuole, have been involved in drug resistance [30–32]. 
These proteins play an important role in trafficking of 
drugs between the parasite cytosol and the food vacu-
ole. Their association with quinoline resistance has 
been demonstrated in many studies [30, 33–35].
But other less studied proteins may be involved in 
molecules traffic within the parasite. The P. falciparum 
Acetyl-CoA transporter (PfACT) and the P. falciparum 
UDP-galactose transporter (PfUGT) [36] are examples 
of major facilitator superfamily transporters and may 
share similar function [37]. The protein PfACT func-
tion is not known yet, but its parasite localization and 
its homologues form in other organisms suggest that 
this protein may be involved in intracellular transloca-
tion of small molecules including metabolites, nucleo-
sides, oligosaccharides, amino-acids, oxyanions and 
drugs. These two putative transporters have been asso-
ciated with in vitro resistance to imidazolopiperazines, 
and more particularly to KAF156 and GNF179, two 
new potential antimalarial compounds that are under 
clinical evaluation [38]. KAF156 showed high in  vitro 
activity and in  vivo efficacy against P. falciparum and 
P. vivax and in vitro and in vivo transmission blocking 
activity [39, 40]. KAF156 did not show in vitro cross-
resistance with artemisinin and lumefantrine [38]. 
GNF179 was active in vitro against blood stages as well 
as liver stages [41]. Resistant parasites to KAF156 and 
GNF179 generated in  vitro showed different muta-
tions (A94T, R108K, S110R, D165N, C183*, S242*, 
L253* and G559K) in the pfact gene and a substitution 
of a phenylalanine by a valine at the position 37 of the 
gene pfugt (F37V) [35]. Additionally, the generation 
of resistant parasites to KAF156 and GNF179 lead to 
mutations (L830V, S1076N/I, V1103L, I1139K) in the 
P. falciparum cyclic amine resistance locus (PfCARL) 
[38, 39, 41–43]. Pfcarl plays a role in protein folding 
within the endoplasmic reticulum [44]. Mutations 
in pfcarl did not lead to in  vitro resistance to arte-
misinin, chloroquine and mefloquine in two mutant 
strains [42]. These three genes seem to be multidrug-
resistance genes specific to resistance to benzimida-
zolyl piperidines and imidazolopiperazines [38, 42, 
43]. However, the data on cross-resistance with stand-
ard anti-malarial drugs were obtained from in  vitro 
selection of P. falciparum mutant clones. Neither the 
involvement of these three genes in resistance to imi-
dazolopiperazines nor cross-resistance with standard 
anti-malarial drugs have been assessed in field iso-
lates. There are no data on polymorphisms and their 
prevalence in natural parasite populations, or in the 
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involvement of these three genes on the susceptibility 
of ACT partner drugs such as piperaquine, pyronari-
dine, lumefantrine or amodiaquine against field P. fal-
ciparum isolates.
The present study aimed to evaluate the prevalence 
of polymorphisms in pfact, pfugt and pfcarl genes and 
to evaluate their association with reduced susceptibil-
ity to common anti-malarial drugs on 259 P. falcipa-
rum African isolates.
Methods
Sample collection
Eighty-six of the samples used were collected from 
falciparum malaria patients, who were recruited at 
the Hôpital Principal de Dakar, Senegal after the rainy 
seasons between 2013 and 2015 in the context of stud-
ies on evaluation of anti-malarial drug resistance [15, 
45–47]. A total of 173 samples collected between 
2015 and 2016 from patients hospitalized in France 
with imported malaria from a malaria-endemic coun-
try, especially from Cameroon, Côte d’Ivoire, Central 
African Republic, Burkina Faso, Togo, Gabon, Guinea 
and Senegal (Fig.  1) were additionally used to com-
plete the study. Twelve samples have an unknown 
African origin. The samples were sent from different 
civilian or military hospitals of the French National 
Reference Centre for Imported Malaria network (Aix 
en Provence, Bordeaux, Fréjus, Marseille, Montpellier, 
Nice, Toulon and Toulouse) to the French National 
Reference Centre for Malaria (IRBA, IHU Méditer-
ranée Infection Marseille).
Peripheral venous blood samples were collected in 
 Vacutainer® ACD tubes (Becton–Dickinson, Ruther-
ford, NJ, USA) prior to patient treatment for parasite 
detection. The diagnosis was performed on thin blood 
smears that were stained using a  RAL® kit (Réactifs 
RAL, Paris, France), based on eosin and methylene blue, 
to determine the P. falciparum density. The diagnosis 
of P. falciparum mono-infection was confirmed by real 
time PCR (LightCycler 2.0, Roche Group, Switzerland), 
as previously described [48]. An aliquot of each sample 
was collected and stored at − 20 °C for molecular study. 
Parasitized erythrocytes were washed three times in 
RPMI 1640 medium (Invitrogen, Paisley, UK) buffered 
with 25 mM HEPES and 25 mM  NaHCO3. If parasitae-
mia exceeded 0.1%, infected erythrocytes were diluted 
to 0.1% with uninfected erythrocytes (human blood 
type A+) and resuspended in RPMI 1640 medium sup-
plemented with 10% human serum (Abcys S.A. Paris, 
France), for a final haematocrit of 1.5%. The suscepti-
bility of the isolates to the different anti-malarial drugs 
was assessed without culture adaptation.
Drugs and ex vivo assay
Chloroquine (CQ), quinine (QN), dihydroartemisinin 
(DHA) and doxycycline (DOX) were obtained from Sigma 
(Saint Louis, MO, USA), monodesethylamodiaquine (DQ) 
from the World Health Organization (Geneva, Switzer-
land), mefloquine (MQ) from Roche (Paris, France), lume-
fantrine (LMF) from Novartis Pharma (Basel, Switzerland), 
and artesunate (AS), piperaquine (PPQ) and pyronaridine 
(PND) from Shin Poong Pharm Co. (Seoul, Korea).
For each experiment, parasitized erythrocytes (final 
parasitemia at 0.5% and a final haematocrit at 1.5%) were 
aliquoted into 96-well plates that were pre-dosed with a 
concentration gradient of anti-malarial drugs. The plates 
were incubated for 72  h at 37  °C in controlled atmos-
phere at 85%  N2, 10%  O2, 5%  CO2 for imported isolates 
and in a sealed bag with atmospheric generators for cap-
nophilic bacteria using Genbag  CO2® at 5%  CO2 and 15% 
 O2 (BioMérieux, Marcy l’Etoile, France) for Senegalese 
isolates [49]. The drug susceptibility assay was performed 
using the HRP2 ELISA-based assay Malaria Ag Celisa kit 
(ref KM2159, Cellabs PTY LDT, Brookvale, Australia), as 
previously described [46].
Each batch of plates was validated using the CQ-resist-
ant W2 strain (isolated in Indochina; obtained from 
MR4, VA, USA) in four independent experiments using 
the same conditions described below.
The mean 50% inhibitory concentration  (IC50) values 
for the chloroquine-resistant W2 strain for the differ-
ent batches used over 2  years in controlled atmosphere 
at 85%  N2, 10%  O2, 5%  CO2 were 484 ± 40  nM for CQ, 
388 ± 29  nM for QN, 97 ± 18  nM for DQ, 1.0 ± 0.4  nM 
for LMF, 26.3 ± 3.1  nM for MQ, 54.1 ± 5.4  nM for PPQ, 
20.4 ± 3.4 nM for PND, 2.5 ± 0.4 nM for DHA, 1.5 ± 0.3 nM 
for AS and 11.5 ± 1.9  µM for DOX. A comparison of 
the W2 susceptibility data of the ten anti-malarial drugs 
between the different batches of plates indicated that there 
was no significant difference in the responses to anti-malar-
ial drugs over the 2  years (0.583 < p < 0.993). The cut-off 
values for the reduced ex  vivo susceptibility or resistance 
were as follows: 100  nM (CQ), 800  nM (QN), 80  nM 
(DQ), 30 nM (MQ), 150 nM (LMF), 135 nM (PPQ), 60 nM 
(PND), 10.5 nM (DHA and AS) and 35 µM (DOX) [50, 51].
The mean  IC50 values for the W2 strain for the differ-
ent batches used during the 3 years using atmospheric 
generators for capnophilic bacteria were 292  nM for 
CQ, 275 nM for QN, 72 nM for DQ, 13.7 nM for LMF, 
15.4 nM for MQ, 32.5 nM for PPQ, 26.4 nM for PND, 
1.27 nM for DHA, and 10.7 µM for DOX. A compari-
son of W2 susceptibility data for the nine anti-malarial 
drugs indicated that there was no significant difference 
in the responses to anti-malarial drugs over the 3 years 
(0.39 < p < 0.95). The cut-off values for the reduced 
ex  vivo susceptibility or resistance were as follows: 
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77 nM (CQ), 611 nM (QN), 61 nM (DQ), 30 nM (MQ), 
115 nM (LMF), 135 nM (PPQ), 60 nM (PND), 12 nM 
(DHA and AS) and 37 µM (DOX) [46, 47, 52].
The polymorphic genetic markers msp1 and msp2 
and microsatellite markers specific to P. falciparum 
were genotyped at least once a month to verify W2 
clonality [53, 54].
Nucleic acid extraction
Total genomic DNA of each sample was isolated and purified 
using the  QIAamp® DNA Mini kit according to the manu-
facturer’s recommendations (Qiagen, Hilden, Germany).
Genotyping of pfact, pfugt and pfcarl
The three genes, pfact (PF3D7_1036800), pfugt 
(PF3D7_1113300) and pfcarl (PF3D7_0321900), were 
amplified by polymerase chain reaction using the oligo-
nucleotide primer pairs described in Table 1.
Two primer pairs were used to amplify the pfact frag-
ments (1042 and 407 nucleotides). The reaction mixture 
contained 200  ng of genomic DNA, 0.32  µM of each 
primer, 1× final of reaction buffer (750 mM of Tris–HCl, 
200  mM of  (NH4)2SO4, 0.1% (v/v) Tween 20 and stabi-
lizer, pH 8.8), 2.5 mM of  MgCl2, 200 µM of dNTP mixture 
and 1 U of Hot Diamond  Taq® polymerase (Eurogentec, 
Fig. 1 Geographical repartition and isolate number per country of the Plasmodium falciparum isolates collected between 2015 and 2016 from 
patients hospitalized in France with imported malaria from Africa
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Liège, Belgium) in a final volume of 25 µL. The thermal 
cycler (Life Eco V 2.04; Bioer, China) was programmed 
as follows: 95 °C for 10 min, 40 cycles of 95 °C for 30 s, 
hybridization temperature for 45  s (Table  1), 72  °C for 
1 min 20 s, and a final 10-min extension step at 72 °C.
A fragment of 600 nucleotides of pfugt gene was ampli-
fied using the two primer pairs described in Table 1. The 
reaction mixture contained 200  ng of genomic DNA, 
0.32  µM of each primer, 1× final of reaction buffer 
(750  mM of Tris–HCl, 200  mM of  (NH4)2SO4, 0.1% 
(v/v) Tween 20 and stabilizer, pH 8.8), 2.5 mM of  MgCl2, 
200 µM of dNTP mixture and 1 U of Hot Diamond  Taq® 
polymerase (Eurogentec, Liège, Belgium) in a final vol-
ume of 25 µL. The thermal cycler (Life Eco V 2.04; Bioer, 
China) was programmed as follows: 95 °C for 10 min, 40 
cycles of 95  °C for 30  s, hybridization temperature for 
45 s (Table 1), 72 °C for 45 s, and a final 10-min extension 
step at 72 °C.
To analyse pfcarl mutations, a fragment of 821 nucle-
otides was amplified using the specific primer pair 
described in Table  1. The reaction mixture contained 
200  ng of genomic DNA, 0.32  µM of each primer, 1× 
final of reaction buffer (750 mM of Tris–HCl, 200 mM of 
 (NH4)2SO4, 0.1% (v/v) Tween 20 and stabilizer, pH 8.8), 
2.5 mM of  MgCl2, 200 µM of dNTP mixture and 1 U of 
Hot Diamond  Taq® polymerase (Eurogentec, Liège, Bel-
gium) in a final volume of 25 µL. The thermal cycler (Life 
Eco V 2.04; Bioer, China) was programmed as follows: 
95 °C for 10 min, 40 cycles of 95 °C for 30 s, hybridization 
temperature for 45 s (Table 1), 72 °C for 1 min, and a final 
10-min extension step at 72 °C.
The purified amplicons were sequenced using corre-
sponding PCR primers and a sequencing primer for pfact 
first fragment (Table  1) on an ABI Prism 3100 analyser 
(Applied Biosystems, Villebon sur Yvette, France) accord-
ing to the manufacturers’ instructions. Sequences were 
aligned and compared with the corresponding sequences 
of the P. falciparum 3D7 using Vector NTI 10.3.0 (Invit-
rogen, Cergy Pontoise, France) to identify potential SNPs.
Data and statistical analysis
Samples and genotype distribution were performed on 
Tableau Desktop (Version 10.3.2). Plots of  IC50 distribu-
tion were performed using R software. Statistical analyses 
were performed on SPSS, Version 16 (IBM, USA). Nor-
mally distributed  IC50s data for each drug were assessed 
by the Kolmogorov–Smirnov test.
Results
Ex vivo susceptibility to anti‑malarial drugs
The average parameters of the  IC50 values for the ten anti-
malarial drugs are presented in Table 2. The distribution 
of the  IC50 values are showed in Fig. 2 for the Senegalese 
isolates and in Fig. 3 for malaria imported isolates.
Gene sequence polymorphism analysis
The previously identified mutations at position 94, 108, 
110, 165, 183, 242, 253 and 559 in the pfact gene were not 
detected and no other polymorphism was identified in 
the 259 African isolates. For the gene pfugt, all samples 
were also wild type at position 37 and no other polymor-
phism was identified within the sequences.
None of the mutations of the pfcarl gene involved 
in imidazolopiperazine resistance was found in Afri-
can P. falciparum isolates. Three new mutations were 
detected: the K784N mutation present in one isolate, 
the K734M mutation (8.9% on Senegalese samples 
and 7.5% on malaria imported samples) and the K903E 
mutation which was found on both all Senegalese and 
malaria imported valid sequences (100%). The only sig-
nificant differences in ex vivo susceptibility according to 
the K734M mutation were observed for PND for Afri-
can isolates from imported malaria (p = 0.028; 22.1  nM 
vs. 39.2  nM) and for DOX for Senegalese parasites 
(p = 0.034; 26.4 µM vs. 8.0 µM) (Table 3). The difference 
in PND  IC50s according to the wild type/mutant hap-
lotype of PfCARL was not significant by pooling all the 
 IC50s from imported and Senegalese isolates (20.4 nM vs. 
30.4  nM; p = 0.202). There was no significant difference 
between the prevalences of 734  M mutated parasites in 
susceptible isolates and that in parasites with reduced 
susceptibility to the different anti-malarial drugs tested in 
the present study (p values between 0.053 and 1 [Fisher’s 
exact test]) (Table 4).
Table 1 Forward and  reverse primers, hybridization 
temperature (Tm) and  MgCl2 concentration used for PCR
Gene Forward and reverse primers Tm
pfugt (PF3D7_1113300) Pfugt-F
5′-GCT CAG GTA TGT TTT GGA AG-3′
Pfugt-R
5′-GTC CAG TAA GTC CGT CAC AT-3′
52 °C
pfact (PF3D7_1036800) Pfact-1F
5′-TTG TGT AAC CCC CAC TAA AC-3′
54 °C
Pfact-1R
5′-TTA TCG TCA CAC TTT TGT GC-3′
Pfact_seq 1F
5′-CTA TTT TGC AGT TTT ACG ATG-3′
54 °C
Pfact-2F
5′-TGA TTA CAC TGA TAA GGA ATT 
TTG-3′
Pfact-2R
5′-TTC GTT CTC CAA TCT TCT AAA-3′
48 °C
pfcarl (PF3D7_0321900) Pfcarl-F
5′-TTG CCA TGA TTT GAA GTA CA-3′
Pfcarl-R
5′-AAC CAT TTT CGT ATT CAT GTT-3′
50 °C
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Discussion
The aim of the present study was to determine whether 
described SNPs in the genes pfact, pfugt and pfcarl, 
involved in imidazolopiperazine resistance, are found in 
African isolates, their prevalence and if these mutations 
are associated with common anti-malarial drug suscep-
tibility. The main limitation of this study is the low num-
ber of parasites with reduced susceptibility to LMF (0% 
for Senegalese isolates and imported isolates), QN (5.7% 
for Senegalese isolates and 0% for imported isolates), 
PND (3.1% for Senegalese isolates and 6.1% for imported 
isolates) and PPQ (6.1% for Senegalese isolates and 0.6% 
for imported isolates). However,  IC50 values were dis-
tributed in a broad way (Figs.  2, 3). There was no poly-
morphism in the analysed sequence of pfact and pfugt. 
None of the mutations of the pfcarl gene involved in 
imidazolopiperazine resistance was found in African P. 
falciparum isolates but three other ones were identified: 
the K784N mutation present in one isolate, the K734M 
mutation (7.9%) (prevalence of 8.9% in Senegalese sam-
ples and 7.5% in malaria imported samples from Africa) 
and the K903E mutation (100%). These mutations were 
also found in P. falciparum sequences filed on PlasmoDB 
in similar proportions: 0.4% for K784N, 11% for K734M 
and 99% for K903E mutation. The K734M seemed to be 
not associated with susceptibility to standard anti-malar-
ial drugs. No evidence was found of prevalence difference 
between susceptible isolates and parasites with reduced 
susceptibility. Only parasites collected from African 
imported malaria carrying the K734M mutation were 
significantly less susceptible to pyronaridine than wild 
P. falciparum parasites (39.2 nM vs. 22.1 nM; p = 0.028). 
However, these data should be taken with caution due 
to the low number of samples, and more specially para-
sites with reduced susceptibility to anti-malarial drugs. 
It is necessary to further assess more P. falciparum iso-
lates to ascertain the potential association between the 
pfcarl K734M mutation and reduced susceptibility to 
pyronaridine.
A limitation of this kind of study is the strength of 
the correlation between ex vivo or in vitro studies and 
therapeutic efficacy assays. Clinical failures with dihy-
droartemisinin/piperaquine in Cambodia were associ-
ated with resistant phenotype but this association has 
not been shown yet in Africa [22, 23, 55]. Association 
between these two methods is not fully established for 
some anti-malarial drugs like mefloquine, lumefan-
trine, piperaquine, pyronaridine, and more particularly 
in Africa. The main explanations for a lack of correla-
tion are that in vitro assays and clinical studies of thera-
peutic efficacy do not address the same biological and 
clinical endpoints and the cut off for in  vitro reduced 
susceptibility are usually fixed arbitrarily without any 
reference to predictable clinical and parasitological 
response [56]. Many factors, and more specially host 
factors like acquired immunity, nutritional status, phar-
macokinetic characteristics, interact in drug in  vivo 
efficacy. However, the major criteria for a valid in vitro 
or ex  vivo threshold should be the association with 
clinical outcome.
Additionally, in the absence of standardized ex  vivo 
and in  vitro tests, it is very difficult to compare data 
Table 2 Average parameters of P. falciparum susceptibility to chloroquine (CQ), quinine (QN), monodesethylamodiaquine 
(DQ), mefloquine (MQ), lumefantrine (LMF), pyronaridine (PND), piperaquine (PPQ), dihydroartemisinin (DHA), 
artesunate (AS) and doxycycline (DOX)
IC50 in nM for CQ, QN, DQ, MQ, LMF, PND, PPQ, DHA, AS
IC50 in µM for DOX
Drugs Isolates from Senegal (n = 86) African isolates from imported malaria analyzed for pfcarl 
(n = 173)
IC50 Geometric 
mean
Resistance % IC50 Geometric mean Resistance %
Min Max Min Max
CQ 0.6 954.9 60.0 48.6 6.27 791.6 69.7 28.3
QN 5 1429.8 113 5.7 5.29 690.1 127.8 0
DQ 1.6 227.3 21.7 23.6 1.9 196.43 29.2 8.1
MQ 2 109.2 24.8 48.5 4.4 173.43 39.5 67.7
LMF 0.5 82.9 4.53 0 0.33 16.66 1.4 0
PND 0.4 116.6 16.4 3.1 0.8 122.96 16.5 6.1
PPQ 3.2 241.9 37.4 6.1 0.94 137.51 34.3 0.6
DHA 0.08 17.28 1.36 1.5 0.09 28.11 4.1 17.5
AS 0.06 18.06 2.18 3.5 0.1 23.56 3.7 9.8
DOX 0.9 121.6 23.0 28.2 0.46 41.14 16.2 17.3
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from different laboratories.  IC50 and cut-off values for 
in vitro resistance are specific to the methodology. The 
in  vitro effects and the  IC50 values for anti-malarial 
drugs depend on incubation conditions [57, 58], gas 
conditions (e.g., the effects of  O2 and  CO2) [45, 59], 
and methodology (e.g., use of an isotopic test vs. an 
immune-enzymatic test) [60]. These differences in 
methodology must be taken into account when com-
paring and analysing resistance data from different 
studies. The use of a reference strain as internal con-
trol is essential to validate and compare data obtained 
with several batches of plates.
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Fig. 2 Dot plot of the  IC50 total distribution of each Senegalese Plasmodium falciparum isolate assessed ex vivo for chloroquine (CQ), quinine 
(QN), monodesethylamodiaquine (DQ), mefloquine (MQ), lumefantrine (LMF), piperaquine (PPQ), pyronaridine (PND), dihydroartemisinin (DHA), 
artesunate (AS) and doxycycline (DOX). The red line represents the in vitro threshold of reduced susceptibility
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Conclusion
None of the mutations of the pfact, pfugt and pfcarl 
genes involved in imidazolopiperazine or benzimida-
zolyl piperidine resistance was found in 259 African 
P. falciparum isolates. The prevalence of these muta-
tions in Africa was very low. This absence of mutations 
involved in imidazolopiperazine or benzimidazolyl 
piperidine resistance suggests that the pfact, pfugt 
and pfcarl genes are not involved in quinoline ex vivo 
resistance (28.3 to 48.6% of resistance to chloroquine, 
8.1 to 23.6% of resistance to desethylamodiaquine 
or 48.5 to 67.7% of resistance to mefloquine) and in 
doxycycline reduced susceptibility (17.3 to 28.2%) 
in the 259 P. falciparum African isolates which were 
evaluated in the present study. Additionally, the 734M 
mutation identified in the pfcarl gene at a rate of 7.9% 
was not associated with ex vivo susceptibility to stand-
ard anti-malarial drugs. This absence of identification 
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Fig. 3 Dot plot of the  IC50 total distribution of each Plasmodium falciparum isolate from imported malaria to France assessed ex vivo for 
chloroquine (CQ), quinine (QN), monodesethylamodiaquine (DQ), mefloquine (MQ), lumefantrine (LMF), piperaquine (PPQ), pyronaridine (PND), 
dihydroartemisinin (DHA), artesunate (AS) and doxycycline (DOX). The red line represents the in vitro threshold of reduced susceptibility
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of the mutations in pfact, pfugt and pfcarl genes, which 
are involved in imidazolopiperazine resistance, in 259 
African P. falciparum isolates, is suggesting a very low 
prevalence of resistant parasites, encouraging data for 
the use of KAF156 and GNF179 for malaria treatment.
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Table 3 Ex vivo susceptibility of  African Plasmodium falciparum isolates to  chloroquine (CQ), quinine (QN), 
monodesethylamodiaquine (DQ), mefloquine (MQ), lumefantrine (LMF), piperaquine (PPQ), pyronaridine (PND), 
dihydroartemisinin (DHA), artesunate (AS) and doxycycline (DOX) according to the K734M mutation in the pfcarl gene
Drug Isolates from Senegal African isolates from imported malaria
Wild‑type K734 (n = 61) Mutated 734M (n = 6) p‑value Wild‑type K734 (n = 160) Mutated 734 M (n = 13) p‑value
Mean  IC50 Min and Max Mean  IC50 Min and Max Mean  IC50 Min and Max Mean  IC50 Min and Max
CQ 110.7 0.6/954.9 87.7 17.0/163 0.835 109.1 7.2/791.6 107.6 6.27/383.8 0.616
QN 225.8 5/1429.8 69.0 15.0/140.1 0.087 176.0 11.53/690.1 137.8 5.29/338.3 0.227
DQ 36.9 1.6/202.6 41.8 2.4/140.0 0.690 37.1 3.72/196.4 39.1 1.9/105.6 0.588
MQ 37.6 2.0/123.0 19.6 10.0/44.0 0.088 48.8 4.4/173.4 60.0 21.16/172.6 0.398
LMF 9.9 0.5/82.9 5.9 1.2/12.6 0.970 2.2 0.33/13.5 2.6 0.37/16.7 0.704
PPQ 56.1 3.2/241.9 37.9 12.0/100.0 0.350 39.9 0.94/137.5 47.4 14.3/96.8 0.293
PND 15.4 0.4/111.6 9.5 4.8/15.2 0.700 22.1 0.8/114.6 39.2 7.09/122.9 0.028
DHA 2.9 0.8/17.3 2.1 0.09/9.2 0.101 6.0 0.19/28.1 7.1 0.09/23.3 0.404
AS 4.2 0.06/18.1 4.6 2.5/8.5 0.709 5.0 0.1/23.6 5.8 1.9/17.9 0.362
DOX 26.4 0.9/79.0 8.0 1.5/18.4 0.034 22.0 0.79/51.1 16.3 0.46/39.4 0.144
Table 4 Prevalences of  Plasmodium falciparum isolates with  the  734M mutation in  the  P. falciparum cyclic amine 
resistance locus (pfcarl) according to  parasite susceptibility to  chloroquine (CQ), quinine (QN), lumefantrine (LMF), 
desethylamodiaquine (DQ), mefloquine (MQ), pyronaridine, (PND), piperaquine (PPQ), dihydroartemisinin (DHA), 
artesunate (AS) and doxycycline (DOX)
a Cutoff estimated for ex vivo test in seal bag with atmospheric generator using Genbag  CO2® [52]
b Cutoff estimated for ex vivo test in controlled atmosphere for imported isolates [50, 51]
Drug Reduced‑susceptible cutoff % of isolates with the 734M mutation (no. of isolates with the 734M 
mutation/total no. of susceptible or resistant isolates
p value 
(Fisher’s 
exact test)
Susceptible parasites Parasites with reduced 
susceptibility
CQ 77a or  100b nM 7.7 (12/155) 8.2 (7/85) 1
QN 611a or  800b nM 8.0 (19/235) 0 (0/5) 1
LMF 150 nM 8.0 (19/235) 0 (0/0) 1
DQ 61a or  80b nM 7.2 (15/209) 12.9 (4/31) 0.28
MQ 30 nM 7.4 (7/95) 6.9 (10/145) 1
PND 60 nM 6.9 (16/233) 28.6 (2/7) 0.089
PPQ 135 nM 7.2 (17/236) 0 (0/4) 1
DHA 12a or 10.5b nM 7.4 (16/217) 13.0 (3/23) 0.41
AS 12 or 10.5 nM 6.7 (15/225) 25.0 (3/12) 0.053
DOX 37a or  35b nM 8.2 (16/194) 6.5 (3/46) 1
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